Orbimed Advisors LLC Increases Stake in Alto Neuroscience, Inc. $ANRO

Orbimed Advisors LLC boosted its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 34.0% during the first quarter, HoldingsChannel reports. The fund owned 167,500 shares of the company’s stock after buying an additional 42,500 shares during the quarter. Orbimed Advisors LLC’s holdings in Alto Neuroscience were worth $3,765,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. boosted its position in Alto Neuroscience by 14,567.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after purchasing an additional 211,222 shares during the period. Jennison Associates LLC bought a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $8,687,000. Artia Global Partners LP bought a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $520,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience during the 1st quarter valued at approximately $538,000. Finally, Commodore Capital LP lifted its stake in shares of Alto Neuroscience by 49.4% during the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after buying an additional 900,000 shares in the last quarter.

Alto Neuroscience Stock Performance

Alto Neuroscience stock opened at $26.72 on Monday. The firm’s 50 day simple moving average is $23.47 and its 200 day simple moving average is $21.53. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $937.53 million, a PE ratio of -11.04 and a beta of 1.04. Alto Neuroscience, Inc. has a 1-year low of $3.00 and a 1-year high of $28.85.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, analysts expect that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ANRO shares. Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Bank of America began coverage on Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price on the stock. Wall Street Zen raised Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Robert W. Baird reduced their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.25.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.